marijuana rescheduling – The DOJ moved some cannabis forms from Schedule I to Schedule III, lowering the federal “risk” label. For weed firms, research may expand—while tax rules and state patchwork remain.
The U.S. just moved some marijuana products to a less restrictive federal classification, a shift that signals Washington may be ready to treat cannabis differently than it has for decades.
The change centers on a DOJ order reclassifying certain forms of marijuana from Schedule I—where drugs like heroin. MDMA. and LSD sit—into Schedule III.. Acting Attorney General Todd Blanche announced the decision and said the department will move state-licensed marijuana and FDA-approved marijuana products into the new category immediately.
What “Schedule III” changes in practice
Schedule I has long been treated as the federal label for the highest-risk substances. typically tied to high abuse potential and no accepted medical use.. Schedule III is different: it covers drugs considered to have a “moderate to low” potential for abuse and a lower likelihood of physical or psychological dependence.
For businesses, regulators, and clinicians, that classification is more than a legal technicality.. A lower schedule can reshape what research institutions are willing to pursue. how clinical trials are approved. and how doctors talk about evidence-based use.. The DOJ framed the move as a way to enable “more targeted, rigorous research” and expand patients’ access to treatments.
Why the DOJ move is a financial story, not just a medical one
Even if it does not equal federal legalization, rescheduling can still shift the economics of the cannabis sector.. Cannabis companies have spent years operating under rules that reflect Schedule I’s severity. including compliance burdens and limits that can discourage investment.. A Schedule III label can make it easier for researchers and some developers to plan long timelines for testing safety and efficacy.
There is also a market psychology component. Cannabis is currently squeezed by fundamentals that have been hard to ignore: a glut of product in parts of the market, weaker demand, and sharply lower prices. In that environment, any regulatory thaw can act like a catalyst—even before profits improve.
A rescheduling step can also change how capital flows.. Investors tend to price regulatory risk heavily. especially when a sector faces uncertainty about how quickly courts. regulators. and tax authorities will respond.. By moving forward where earlier attempts stalled. Misryoum sees the DOJ action as an attempt to reduce friction for the next phase—potentially including a faster path toward further changes.
The road ahead: hearings, court history, and federal-state mismatch
Blanche said the DOJ will order a new “expedited hearing” as part of a process that could lead to marijuana being fully rescheduled at the federal level. That hearing is expected in June, and it would be a necessary step if the government were to consider legalization federally.
The timing matters because the broader rescheduling effort has met resistance before.. In 2023. Biden’s Department of Health and Human Services recommended moving marijuana to Schedule III. but the process stalled in court.. Misryoum’s read on the moment is that this administration is trying to avoid the kind of legal delays that keep the industry in limbo.
Still, rescheduling does not untangle the state-by-state reality.. Cannabis is legal for medical use in many states, and adult recreational markets exist in a smaller—though growing—set.. But federal and state systems still operate with limited alignment. leaving companies to navigate a patchwork that complicates everything from product standards to distribution planning.
The tax question remains: 280E and the profit squeeze
For most cannabis operators, one of the most painful constraints is the tax structure created by IRS Section 280E.. Under that rule. cannabis businesses generally can’t use the same deductions and credits available to many other industries. and they often pay taxes on gross income rather than adjusted income.. The result can be an effective tax burden that becomes especially damaging when prices fall.
Rescheduling to Schedule III could create opportunities for tax relief—but not automatically.. Misryoum expects the IRS to have to determine how 280E should apply in a world where marijuana is no longer treated as Schedule I.. Until that happens, many companies may remain stuck with high effective rates, even if their regulatory posture improves.
This is where the stakes get real for owners and workers. When effective taxes remain high, margins stay thin, hiring slows, and consolidation pressures can grow—especially during periods of price weakness. A regulatory upgrade helps, but it doesn’t fix balance sheets by itself.
Cannabis and the broader federal drug agenda
The rescheduling move also sits inside a wider federal push to accelerate research and modernize drug policy. The administration has indicated it is moving ahead on psychedelic-related research as well, including compounds like psilocybin and MDMA for therapeutic study.
For the cannabis industry, the practical takeaway is that marijuana may be entering a new category of federal engagement—one that treats cannabis less like a blanket public-health threat and more like a substance that can be evaluated through controlled medical evidence.
Yet uncertainty won’t disappear overnight. The legal status at the federal level is still not the same as full legalization, and interstate commerce remains constrained by how federal rules interact with state frameworks.
What to watch next
Misryoum will be watching three things as the June hearing approaches.. First, whether the government moves from partial rescheduling toward further changes.. Second, how courts and regulators handle the next procedural steps after the earlier stalling.. Third. and perhaps most important for profitability. whether the IRS updates or interprets 280E in ways that meaningfully reduce the effective tax load.
For cannabis businesses, the immediate win is a regulatory signal: the “danger label” is getting lighter.. The next question is whether that signal turns into tangible relief—through research pathways. investor confidence. and tax clarity—before the industry’s current financial pressure builds further.
Bluesky boosts photo quality—bigger uploads and sharper renders
AI sycophancy: the hidden risk beyond social media bubbles
JetBlue privacy lawsuit: personal data and ‘surveillance pricing’ claims